Drug profile

The FDA adverse-event record for N-Butylscopolaminium Bromide

92 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference N-Butylscopolaminium Bromide. See the species affected, top reactions, and outcomes below.

92
adverse-event reports
40.2%
death-coded share
Horse
most-reported species
24
Death by euthanasia - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
92
Total Reports
37
Deaths Reported
40.2%
Death Rate

Active Ingredients

N-Butylscopolaminium Bromide

Administration Routes

UnknownIntravenousIntramuscularOral

Species Affected

Horse 73
Unknown 16
Human 2
Donkey 1

Most Affected Breeds

Unknown 19
Quarter Horse 10
Warmblood (unspecified) 9
Horse (unknown) 8
Thoroughbred 7
Paint 6
Arab 6
Crossbred Equine/horse 4
Miniature 4
Pony (unspecified) 3

Most Reported Reactions

Death by euthanasia 24
Colic 14
Other abnormal test result NOS 13
Death 11
Vials, Damaged 10
Lack of efficacy - NOS 9
Ataxia 7
Recumbency 6
Tachycardia 5
Abnormal ultrasound finding 5
Fever 5
Anorexia 5

Outcome Breakdown

Recovered/Normal
31 (40.3%)
Euthanized
26 (33.8%)
Died
11 (14.3%)
Outcome Unknown
6 (7.8%)
Ongoing
2 (2.6%)
Recovered with Sequela
1 (1.3%)

N-Butylscopolaminium Bromide Adverse Event Insights

92 reports name N-Butylscopolaminium Bromide; 37 recorded a death outcome (40.2% of reported events, not a population-level mortality rate). Active ingredient: N-Butylscopolaminium Bromide. Administration routes: Unknown, Intravenous, Intramuscular, Oral.

By species: Horse (73 reports), Unknown (16 reports), Human (2 reports). By breed: Unknown (19), Quarter Horse (10), Warmblood (unspecified) (9).

Leading clinical signs: Death by euthanasia (24), Colic (14), Other abnormal test result NOS (13), Death (11). Outcome, 77 coded reports: Recovered/Normal leads at 40.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.